T cells expressing membrane-anchored IL-12 for the treatment of cancer
US11421010B2 · kind B2 · utility
1Cited by
1References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 6, 2017 |
| Grant date | Aug 23, 2022 |
| Priority date | — |
| Expiry date | Dec 30, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are polypeptides comprising membrane-anchored IL-12. Also provided herein are T cells expressing the membrane-anchored IL-12. Further, methods of treating cancer comprising administering T cells expressing membrane-anchored IL-12 are provided herein. Also provided are combination treatments comprising T cells expressing membrane-anchored IL-12 and T cell chemoattractant-inducing chemokines. In addition, methods are provided for activating T cells to express NKG2D and methods of their use in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.